DE2314388C3 - Arzneimittel antitumoraler Wirkung mit einem Gehalt an Pibromin - Google Patents
Arzneimittel antitumoraler Wirkung mit einem Gehalt an PibrominInfo
- Publication number
- DE2314388C3 DE2314388C3 DE19732314388 DE2314388A DE2314388C3 DE 2314388 C3 DE2314388 C3 DE 2314388C3 DE 19732314388 DE19732314388 DE 19732314388 DE 2314388 A DE2314388 A DE 2314388A DE 2314388 C3 DE2314388 C3 DE 2314388C3
- Authority
- DE
- Germany
- Prior art keywords
- sarcoma
- preparation
- tumor
- formula
- coch
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 230000000259 anti-tumor effect Effects 0.000 title claims description 14
- 229940079593 drug Drugs 0.000 title claims description 7
- 239000003814 drug Substances 0.000 title claims description 7
- 238000002360 preparation method Methods 0.000 claims description 30
- 206010028980 Neoplasm Diseases 0.000 claims description 21
- 206010039491 Sarcoma Diseases 0.000 claims description 19
- 239000004480 active ingredient Substances 0.000 claims description 6
- 229960000952 pipobroman Drugs 0.000 claims description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 3
- 231100000331 toxic Toxicity 0.000 claims description 3
- 230000002588 toxic effect Effects 0.000 claims description 3
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 208000008601 Polycythemia Diseases 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 150000004820 halides Chemical class 0.000 claims description 2
- 201000000306 sarcoidosis Diseases 0.000 claims description 2
- LRANPJDWHYRCER-UHFFFAOYSA-N 1,2-diazepine Chemical compound N1C=CC=CC=N1 LRANPJDWHYRCER-UHFFFAOYSA-N 0.000 claims 1
- VNBAOSVONFJBKP-UHFFFAOYSA-N 2-chloro-n,n-bis(2-chloroethyl)propan-1-amine;hydrochloride Chemical compound Cl.CC(Cl)CN(CCCl)CCCl VNBAOSVONFJBKP-UHFFFAOYSA-N 0.000 claims 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 206010023841 laryngeal neoplasm Diseases 0.000 claims 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- 239000002547 new drug Substances 0.000 claims 1
- 229920001451 polypropylene glycol Polymers 0.000 claims 1
- 229950004157 sarcolysin Drugs 0.000 claims 1
- 231100000027 toxicology Toxicity 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 241000700159 Rattus Species 0.000 description 13
- 208000009331 Experimental Sarcoma Diseases 0.000 description 12
- 230000005764 inhibitory process Effects 0.000 description 11
- 230000004614 tumor growth Effects 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- OFQCQIGMURIECL-UHFFFAOYSA-N 2-[2-(diethylamino)ethyl]-2',6'-dimethylspiro[isoquinoline-4,4'-oxane]-1,3-dione;phosphoric acid Chemical compound OP(O)(O)=O.O=C1N(CCN(CC)CC)C(=O)C2=CC=CC=C2C21CC(C)OC(C)C2 OFQCQIGMURIECL-UHFFFAOYSA-N 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- NJBFOOCLYDNZJN-UHFFFAOYSA-N pipobroman Chemical compound BrCCC(=O)N1CCN(C(=O)CCBr)CC1 NJBFOOCLYDNZJN-UHFFFAOYSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 231100000682 maximum tolerated dose Toxicity 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 201000000274 Carcinosarcoma Diseases 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 231100001231 less toxic Toxicity 0.000 description 3
- 239000008023 pharmaceutical filler Substances 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 208000006268 Sarcoma 180 Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000000973 chemotherapeutic effect Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 206010006895 Cachexia Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 206010043515 Throat cancer Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 229910000039 hydrogen halide Inorganic materials 0.000 description 1
- 239000012433 hydrogen halide Substances 0.000 description 1
- 230000001096 hypoplastic effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000008063 pharmaceutical solvent Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000001373 regressive effect Effects 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SU1762495 | 1972-03-22 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DE2314388A1 DE2314388A1 (de) | 1973-10-11 |
| DE2314388B2 DE2314388B2 (de) | 1978-08-03 |
| DE2314388C3 true DE2314388C3 (de) | 1979-04-05 |
Family
ID=20507495
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19732314388 Expired DE2314388C3 (de) | 1972-03-22 | 1973-03-22 | Arzneimittel antitumoraler Wirkung mit einem Gehalt an Pibromin |
Country Status (3)
| Country | Link |
|---|---|
| DE (1) | DE2314388C3 (enExample) |
| FR (1) | FR2187331B1 (enExample) |
| GB (1) | GB1406176A (enExample) |
-
1973
- 1973-03-22 DE DE19732314388 patent/DE2314388C3/de not_active Expired
- 1973-03-22 GB GB1381773A patent/GB1406176A/en not_active Expired
- 1973-03-22 FR FR7310329A patent/FR2187331B1/fr not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| FR2187331B1 (enExample) | 1975-10-31 |
| DE2314388A1 (de) | 1973-10-11 |
| GB1406176A (en) | 1975-09-17 |
| DE2314388B2 (de) | 1978-08-03 |
| FR2187331A1 (enExample) | 1974-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69424441T2 (de) | (2,4-disulfophenyl) n-tertiär butyl nitron, seine salze und ihre verwendung als pharmazeutische radikalfänger | |
| EP0240829A2 (de) | Cancerostatisches Mittel | |
| EP0013983A2 (de) | Antineoplastische Mittel auf Basis von nicht oder nur geringfügig irritierenden und/oder promovierenden Diterpenalkoholen und Derivaten davon und deren Herstellung | |
| DE2314388C3 (de) | Arzneimittel antitumoraler Wirkung mit einem Gehalt an Pibromin | |
| DE3134709A1 (de) | Antineoplastisch wirkende titanverbindung und diese enthaltende arzneimittel | |
| DE1695298C3 (de) | S-Acetamido-e-methyl-e-n-propyl-striazolo eckige Klammer auf 4,3-a eckige Klammer zu pyrazin und Verfahren zu seiner Herstellung und Arzneimittel | |
| DE2314387C3 (de) | Arzneimittel zur Behandlung bösartiger Neubildungen | |
| DE2722916A1 (de) | Pharmazeutische zusammensetzung | |
| DE69717961T2 (de) | Verwendung eines flavonoid enthaltenden extraktes der planze euphorbia prostrata zur herstellung eines medikamentes zur behandlung von anoraktalen oder kolonbeschwerden | |
| DE1963223A1 (de) | Mittel zur Behandlung von Virusinfektionen | |
| DE10138561A1 (de) | Tumorhemmende Cerverbindungen | |
| DE2145359A1 (de) | Neue Phthalazindenvate | |
| DE1768376C3 (de) | Aluminium - N-acetylglycinat und dieses als Wirkstoff enthaltende therapeutische Präparate | |
| DE10138538C2 (de) | Tumorhemmende Lanthanverbindungen | |
| DE10116527C2 (de) | Tumorhemmende Galliumverbindungen, deren Verwendung als Arzneimittel sowie ein Arzneimittel, diese enthaltend | |
| DE1620177B2 (de) | N-(2-Hydroxyäthyl) -piperazinocarboxymethyl-te tr acy elin, dessen pharmakologisch verwendbaren Salze, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel | |
| DE2350223A1 (de) | Ein in 4-stellung substituiertes 2-(3-pyridyl)thiazol enthaltendes pharmazeutisches mittel und seine verwendung | |
| DE3333008C2 (enExample) | ||
| DE1768878C (de) | Tetracyclylmethyl p methvlamino benzoesäure, deren pharmakologisch vertraglichen Salze mit Basen oder Sauren und diese enthaltende thera peutische Mischungen | |
| DE2119082C3 (de) | Oral verabreichbares Arzneipräparat mit Serumcholesterinspiegelsenkender. Wirkung | |
| DE3427786A1 (de) | Inklusionskomplexe von benzimidazolderivaten mit cyclodextrinen, deren herstellung und arzneimittel | |
| DD202556A5 (de) | Verfahren zur herstellung von abkoemmlingen von 2-amino-5-(o-sulphamidophenyl)-1,3,4-thiadiazol | |
| DE2362695A1 (de) | Neue 2,7-bis basische vinylenderivate von xanthen und thioxanthen, verfahren zu ihrer herstellung sowie diese enthaltende pharmazeutische zusammensetzungen | |
| DE1518443C (de) | 2-(2,6-Dimethoxyphenoxyäthyl)-aminomethyl-l,4-benzodioxan und dessen Hydrochlorid sowie Verfahren zu deren Herstellung | |
| EP0414895A1 (de) | Orotat der -g(a)-amino--g(b)-phenyl-buttersäure |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C3 | Grant after two publication steps (3rd publication) | ||
| 8328 | Change in the person/name/address of the agent |
Free format text: VON FUENER, A., DIPL.-CHEM. DR.RER.NAT. EBBINGHAUS, D., DIPL.-ING., PAT.-ANW., 8000 MUENCHEN |
|
| 8339 | Ceased/non-payment of the annual fee |